share_log

Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024

Benzinga ·  May 22 08:13

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –

– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –

DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment